



# Report to Board of Directors

For Information

## Finance Report

### August 2022 (Month 5), FY23

#### Contents

##### Executive Summary

1. Income Statement
2. Clinical Income
3. Non-Clinical Income
4. Agency
5. Expenditure by Service Line
6. Cost Improvement Plan
7. Statement of Position
8. Cash-flow
9. Working Capital Indicators
10. Capital Investment Programme
11. Reconciliation to NHSI Template

*A risk assessment has been undertaken around the legal issues that this paper presents and there are no issues that need to be referred to the Trust Solicitors.*

## Executive Summary

	Month 5	Year-to-Date
EBITDA performance	£2.6m surplus, £1.1m favourable to plan	£6.8m surplus, £1.7m favourable to plan
I&E performance	£1.3m surplus, £1.1m favourable to plan	£0.5m surplus, £1.8m favourable to plan
Cost Improvement Plan	£0.2m, £0.5m adverse to plan	£1.3m, £1.9m adverse to plan
Cash	Increase £17.8m	£73.4m, £9.8m favourable to plan

- The year-to-date I&E position as at month 5 is a **£0.5m** surplus, **£1.8m** favourable to plan. EBITDA is a **£6.8m** surplus, **£1.7m** favourable to plan.
- The FY23 plan submitted to NHSE is for **£6.2m** deficit due to two outstanding contractual issues: with NHSE Spec Comm (**£3.5m**) and BOB MHIS (**£5.7m**). OHFT has accepted an additional **£1.5m** ICS CIP to assist BOB with a breakeven plan submission. The plan also includes **£1.2m** tariff from BOB which OHFT have committed not to spend in FY23.
- I&E is **£1.8m** favourable to plan due release of Covid funding (**£3.0m**) and Reserves and deferred income. However, this masks the operational issues of under delivery of CIP **£1.9m** and continuation of high level of agency and contracted OAPS both reported as Covid spend in FY22. Whilst there is some progress these issues are yet to be fully addressed.
- The CIP plan for the year is **£7.9m** (excluding the additional ICS CIP of **£1.5m**) with delivery profiled evenly over 12 months. **£1.3m** has been delivered at month 5, this is **£1.9m** adverse to plan. Whilst it is recognised this is due to delay in CIP engagement as a result of Covid-19, CIP targets are a direct consequence of reduced income set by commissioners in line with NHS efficiency requirements; they are required to reduce the gap between the level of revenue and the expenditure incurred. Plans to reduce expenditure and increase efficiency need to be formulated post Covid.
- The closing cash position at the end of July was **£73.4m**.

**Recommendation:**

The Board of Directors are asked to note the Finance Report against plan and seek any further assurances as required.

# 1. Income Statement

Confidential

INCOME STATEMENT													
Prior Year				Month 5				Year-to-Date					
YTD Actual M4	Change			Plan	Actual	Variance		Plan	Actual	Variance			
£m	£m	%		£m	£m	£m	%	£m	£m	£m	%		
172.1	22.8	13.2%	Clinical Income	40.5	40.9	0.4	0.0%	189.4	194.8	5.4	2.9%		
35.7	-0.9	-2.5%	Other Operating Income	6.5	6.3	-0.2	0.0%	27.0	34.8	7.7	28.6%		
<b>207.7</b>	<b>21.9</b>	<b>10.5%</b>	<b>Operating Income, Total</b>	<b>47.0</b>	<b>47.2</b>	<b>0.2</b>	<b>0.0%</b>	<b>216.5</b>	<b>229.6</b>	<b>13.1</b>	<b>6.1%</b>		
135.2	-10.9	-8.1%	Employee Benefit Expenses (Pay)	29.0	30.7	-1.7	0.0%	134.3	146.1	-11.8	-8.8%		
66.8	-9.9	-14.8%	Other Operating Expenses	16.4	13.8	2.6	0.0%	77.0	76.7	0.4	0.5%		
<b>202.0</b>	<b>-20.8</b>	<b>-10.3%</b>	<b>Operating Expenses, Total</b>	<b>45.5</b>	<b>44.6</b>	<b>0.9</b>	<b>0.0%</b>	<b>211.4</b>	<b>222.8</b>	<b>-11.4</b>	<b>-5.4%</b>		
0.0	0.0	0.0%	Non-Operational Income	0.0	0.0	0.0	0.0%	0.0	0.0	0.0	0.0%		
<b>5.8</b>	<b>1.0</b>	<b>17.4%</b>	<b>EBITDA</b>	<b>1.5</b>	<b>2.6</b>	<b>1.1</b>	<b>0.0%</b>	<b>5.1</b>	<b>6.8</b>	<b>1.7</b>	<b>33.4%</b>		
0.0	-0.1	0.0%	Profit/(Loss) on asset disposal	0.0	0.0	0.0	0.0%	0.0	-0.1	0.1	0.0%		
2.6	-2.2	-83.3%	Depreciation and Amortisation	0.9	1.0	-0.1	0.0%	4.5	4.8	-0.3	-7.8%		
0.0	0.0	0.0%	Asset Impairment	0.0	0.0	0.0	0.0%	0.0	0.0	0.0	0.0%		
0.4	0.2	54.6%	Interest	0.1	0.0	0.1	0.0%	0.4	0.1	0.2	63.2%		
0.3	0.0	0.0%	Other Finance Charge	0.1	0.1	0.0	0.0%	0.3	0.3	0.0	-0.5%		
0.9	-0.2	-21.5%	PDC Dividend	0.2	0.2	0.0	0.0%	1.2	1.1	0.1	8.6%		
<b>1.5</b>	<b>-1.3</b>	<b>0%</b>	<b>Surplus/ (Deficit)</b>	<b>0.3</b>	<b>1.3</b>	<b>1.1</b>	<b>0.0%</b>	<b>-1.3</b>	<b>0.5</b>	<b>1.8</b>	<b>-138.2%</b>		

The month 5 YTD I&E position is a **£0.5m** surplus, **£1.8m** favourable to plan (**£0.8m** deficit, **£0.7m** favourable to plan at month 4). EBITDA is a **£6.8m** surplus, **£1.7m** favourable to plan.

1. Clinical income is favourable to plan by **£5.4m** YTD, driven by recovery of costs from commissioners in Children's Continuing Healthcare and the release of income deferred from FY22 mainly in the Oxfordshire and BSW directorate. The prior year increase of **£22.8m** is due to inflation funding (**£3.3m**), the full year effect of Secure and Adult Eating Disorders Provider Collaboratives and commissioner funded investments in clinical services in the Oxfordshire & BSW and Buckinghamshire directorates.
2. Non-Clinical income is favourable to plan by **£7.7m** YTD, mainly due to retrospective top up payments for Covid-19 costs which are not part of the Covid-19 allocation for the costs of running the vaccination sites. The prior year decrease of **£0.9m** is due to a reduction in Covid-19 income for the vaccination sites of **£3.2m** offset with increased sales in OPS post Covid of **£2.6m** and an increase in Education & Training income.
3. Employee Benefits Expenses (Pay) is **£11.8m** adverse to plan YTD due to staff costs at the mass vaccination centres (**£2.7m**) and continuation of high level of agency reported as Covid spend in FY22 partially expected to taper down in the last 6 months although this requires proactive management action. Medical staffing and CIP under delivery are other major items that need to be addressed. The prior year increase of **£10.9m** is due to inflation, an increase in employers NI and new investment costs in the Oxfordshire & BSW and Buckinghamshire directorates as a result of clinical investment in these services, partially offset by a reduction in costs relating to the Covid mass vaccination sites.
4. Other Operating Expenses (Non Pay) is **£0.4m** favourable to plan YTD, driven by budget held centrally in Reserves. The prior year increase of **£9.9m** due to the full year effect of Secure and Adult Eating Disorders provider collaboratives and increased cost of sales in OPS.
5. The I&E performance in FY23 is **£1.3m** worse than in FY22 due to a deficit plan submitted in FY23.

## Covid-19 Costs

**FY23 Directorate COVID Funding** **-7,318**

Correct Inpatient establishments - community	712	Per ME Review
Correct Inpatient establishments - MH	1,199	Per ME Review
PPE & Testing Team	646	Retained as-is until further guidance
OOA Beds	1,399	Phased downward
Additional staffing support	2,518	Phased downward
Additional cleaning	834	Retained as-is until further guidance

**-10**

<b>Profile:</b>	<b>M1</b>	<b>M2</b>	<b>M3</b>	<b>M4</b>	<b>M5</b>	<b>M6</b>	<b>M7</b>	<b>M8</b>	<b>M9</b>	<b>M10</b>	<b>M11</b>	<b>M12</b>	
Correct Inpatient establishments - community	59	59	59	59	59	59	59	59	59	59	59	59	<b>712</b>
Correct Inpatient establishments - MH	100	100	100	100	100	100	100	100	100	100	100	100	<b>1,199</b>
PPE & Testing Team	54	54	54	54	54	54	54	54	54	54	54	54	<b>646</b>
OOA Beds	373	373	280	187	93	93	0	0	0	0	0	0	<b>1,399</b>
Additional staffing support	775	581	387	387	194	194	0	0	0	0	0	0	<b>2,518</b>
Additional cleaning	70	70	70	70	70	70	70	70	70	70	70	70	<b>834</b>
	<b>1,430</b>	<b>1,237</b>	<b>950</b>	<b>856</b>	<b>570</b>	<b>570</b>	<b>283</b>	<b>283</b>	<b>283</b>	<b>283</b>	<b>283</b>	<b>283</b>	<b>7,308</b>

The Trust's retained Covid-19 funding is **£9.5m** of which **£7.3m** is retained to support:

- **£1.9m** Inpatient cost pressures
- **£1.5m** PPE & Testing Team and additional cleaning
- **£3.9m** additional ward staffing and OOA beds in line with current spend, tapering down on the assumption costs will reduce.

## Performance against Plan

	Plan YTD		Actual YTD		Actual YTD		Actual YTD	
	M5 FY23	M5 FY23	Variance		M5 FY22	Change		
	£'000	£'000	£'000	%	£'000	£'000	%	
Block	170,922	175,951	5,029	3%	152,166	23,785	16%	①
Cost & Volume	4,224	3,844	-380	-9%	5,351	-1,506	-28%	②
Cost Per Case	1,461	1,636	175	12%	2,350	-714	-30%	③
CQUIN	1,397	1,397	0	0%	1,370	27	2%	
Local Authority	9,092	9,651	559	6%	8,443	1,208	14%	④
Section 75 (pooled budget)	2,248	2,263	15	1%	2,340	-77	-3%	
Private Patients	86	99	13	16%	71	28	39%	
<b>Clinical Income Total</b>	<b>189,431</b>	<b>194,842</b>	<b>5,411</b>	<b>3%</b>	<b>172,092</b>	<b>22,750</b>	<b>13%</b>	
Education And Training	6,939	8,265	1,326	19%	7,670	595	8%	⑤
Research & Development	4,943	4,863	-80	-2%	5,667	-803	-14%	⑥
FRF/Top Up Payment	0	6,053	6,053	0%	9,281	-3,228	-35%	⑦
Accommodation	385	496	111	29%	395	101	26%	
Catering	0	0	0	0%	0	0	0%	
Non-Patient Care to Other Bodies	1,578	1,547	-32	-2%	1,982	-436	-22%	
Other Income	801	922	121	15%	434	488	112%	
Parking	31	0	-31	-100%	0	0	0%	
Oxford Pharmacy Sales	12,342	12,605	263	2%	10,223	2,383	23%	⑧
<b>Other Operating Income Total</b>	<b>27,019</b>	<b>34,751</b>	<b>7,732</b>	<b>29%</b>	<b>35,652</b>	<b>-900</b>	<b>-3%</b>	
Permanent	132,099	108,545	23,554	18%	100,459	-8,086	-8%	⑨
Flexible	2,215	11,703	-9,489	-428%	11,175	-528	-5%	⑩
Agency	2	25,892	-25,890	N/A	23,569	-2,324	-10%	⑪
<b>Employee Benefits Expenses</b>	<b>134,316</b>	<b>146,141</b>	<b>-11,825</b>	<b>-9%</b>	<b>135,203</b>	<b>-10,938</b>	<b>8%</b>	
Clinical Services & Supplies	7,917	10,115	-2,198	-28%	10,107	-8	0%	⑫
Drugs	13,063	13,759	-696	-5%	11,223	-2,536	23%	⑬
PFI	245	472	-227	-93%	353	-119	34%	
Car Park Security	0	0	0	0%	0	0	0%	
Premises And Fixed Plant	4,041	4,266	-225	-6%	6,310	2,044	-32%	⑭
Premises - Business Rates	585	347	238	41%	577	230	-40%	
Secondary Commissioning	0	0	0	0%	0	0	0%	
Purchase Of Healthcare	30,433	32,687	-2,253	-7%	26,106	-6,580	25%	⑮
Establishment Expenditure	3,526	3,838	-312	-9%	3,355	-483	14%	
Insurance	207	200	7	4%	215	15	-7%	
Audit Fees External	36	42	-6	-17%	24	-18	75%	
Audit Fees Internal	41	54	-12	-29%	36	-17	47%	
Clinical Negligence	345	439	-93	-27%	345	-94	27%	
Consultancy	21	55	-34	-166%	4	-51	1284%	
General Supplies And Services	1,065	1,591	-526	-49%	1,343	-248	18%	
Legal Fees	95	127	-31	-33%	173	46	-27%	
Losses And Special Payments	8	31	-23	-303%	6	-25	443%	
NHS Services	0	0	0	0%	0	0	0%	
Other Non-Pay Expenditure	11,789	5,053	6,736	57%	3,244	-1,809	56%	⑯
Other Services	241	236	4	2%	245	8	-3%	
Patient Travel	0	0	0	0%	0	0	0%	
Provisions	23	232	-209	-890%	310	0	0%	
Redundancy Costs	0	41	-41	0%	73	32	0%	
Training & Conferences	768	766	2	0%	633	-133	21%	
Transport - Business Travel	1,615	862	753	47%	921	58	-6%	
Transport - Other	976	1,442	-466	-48%	1,153	-289	25%	
Inventory Dhsc Covid Response	0	0	0	0%	0	0	0%	
<b>Total Other Operating Expenses</b>	<b>77,042</b>	<b>76,655</b>	<b>386</b>	<b>1%</b>	<b>66,755</b>	<b>-9,978</b>	<b>15%</b>	
<b>EBITDA Total</b>	<b>5,093</b>	<b>6,797</b>	<b>1,705</b>	<b>33%</b>	<b>5,786</b>	<b>1,011</b>	<b>17%</b>	

EBITDA is a **£6.8m** surplus, **£1.7m** favourable to plan YTD at month 5. The main drivers of the position are:

1. Block income **£5.0m** favourable - in the Community directorate Oxon Children's CHC **£1.3m** to partially offset the high equipment spend, Respiratory Long Covid-19 **£0.1m** released income to match spend, Ageing Well **£0.5m** deferred income released to match expenditure. **£2.0m** favourable in the Oxfordshire & BSW directorate driven by the release of deferred income from FY22. The Buckinghamshire directorate is **£0.7m** favourable driven by the release of deferred income from FY22 to match spend; Other **£0.4m** favourable.
2. Local Authority income **£0.6m** favourable due to unplanned HV income.
3. Education and Training **£1.3m** favourable – Oxfordshire & BSW **£0.7m** due to various training posts where budget has not yet been set; Learning & Development **£0.4m** due to Health Education England income received for trainees, backdated Apprenticeship levy income & income released to match spend. Other **£0.2m**.
4. FRF/Top up Payment **£6.1m** favourable – this is the retrospective top up payments for Covid-19 costs which are not part of the Covid-19 allocation. **£6.1m** is for the costs of running the vaccination sites.
5. Employee Benefits Expenses (Pay) **£11.8m** adverse - **£5.7m** of this is due to staff at the mass vaccination centres. Continuation of high level of agency (c.**£3.6m**) reported as Covid spend in FY22 partially mitigated by release of covid funding c.**£3.1m** in expectation of the tapering down of these expenditure items. Medical staffing c.**£3.1m** adverse exacerbated by high agency usage, CIP under delivery **£1.7m**. Other **£0.8m** adverse.
6. Clinical Supplies and Services **£2.2m** adverse - **£1.4m** overspend on Childrens Continuing Healthcare which is recovered from commissioners, **£0.2m** due to an overspend on Learning Disabilities out of area inpatient stays, **£0.2m** additional capacity purchased from Elmore for complex needs patients offset with additional income and **£0.4m** due to other smaller overspends.
7. Drugs **£0.7m** adverse - **£0.4m** due to higher cost of sales in Oxford Pharmacy Store, **£0.2m** overspend in Oxfordshire adults' mental health and **£0.1m** overspend in Buckinghamshire adults' mental health.
8. Purchase of Healthcare **£2.3m** adverse - **£0.9m** overspend on Provider Collaboratives which is offset by additional income. Out of Area placements are **£1.6m** adverse to plan. These are offset by additional funding from the provider collaboratives for extra packages of care in the Forensic service.
9. General Supplies and Services **£0.5m** adverse – due to an overspend in the Oxfordshire Training Hub **£0.4m** which is offset with budget in the Other Non-Pay Expenditure category and **£0.1m** made up of other smaller variances..
10. Other Non Pay Expenditure **£6.7m** favourable – **£5.6m** is due to centrally held reserves, **£0.8m** is an underspend in the Oxfordshire Training Hub (partially offset with General Supplies & Services) and **£0.3m** is made up of other smaller variances.
11. Transport **£0.8m** favourable – due to reduced business travel post Covid.


Performance against Prior Year

The EBITDA position is £1.1m better than last financial year. The significant changes from FY22 are:

- 1. Block income is £23.8m higher than last year due to inflation c.£3.7m; full year effect of secure and AED provider collaboratives £8.0m; investments in mental health services £15.1m, investments in the Ageing Well Service £1.2m and GP Out of Hours income changing from Cost & Volume to Block £1.1m, offset with a reduction in Covid-19 income of £5.3m.
- 2. Cost & Volume income is £1.5m less than last year - £1.1m of this is due to GP Out of Hours income moving to Block, £0.5m is due to underperformance in Adult Eating Disorders offset by £0.1m made up of other smaller variances.
- 3. Cost per case income is £0.7m lower than last year due to a reduction in income in the Podiatry service.
- 4. Local Authority income is £1.2m higher than last year due to investment in the Buckinghamshire CAMHS service £0.8m and HIV income in the Community directorate £0.4m.
- 5. Education and Training £0.6m higher than last year due to additional training posts in the Institute of Clinical Psychology Training £0.8m offset with a reduction in IAPT trainees' income.
- 6. Research & Development income is £0.8m less than last year due to a £0.3m reduction in Academic Health Science Network income, £0.3m less income now the Novavax clinical trial has ended and a reduction in RCF income in FY23 (this is calculated based on previous years NIHR grant awards payments).
- 7. FRF/Top up Payment £3.2m less than last year due to reduction in Covid funding.
- 8. Oxford Pharmacy Store sales have increased post Covid by £2.4m.
- 9. Permanent staff costs have increased by £8.1m from last year, due to £2.9m FY22 inflation; £2.8m FY23 inflation; continued Covid-19 costs in Community Hospitals (£2.2m) and in the GP Out of Hours service (£0.4m); £0.7m in Ageing Well, new costs in Oxfordshire & BSW MH and Buckinghamshire MH directorates as a result of investment in these services last year £0.6m; £1.1m FY23 increase in employers NI. This is offset with a £2.4m reduction in Covid costs and a net £0.2m decrease in other areas.
- 10. Flexible staff costs have increased by £0.5m. Covid flexible staff costs are £1.5m less than last year. £0.3m of the increase is due to FY22 pay inflation and the main increase is in clinical directorates due to investment and to avoid the use of agency.
- 11. Agency staff costs have increased by £2.3m from last year. £0.7m of this increase is due to FY22 inflation; £4.6m is due to new costs in Oxfordshire & BSW MH and Buckinghamshire MH directorates as a result of investment in these services last year, £1.3m is due to prior year agency costs in the FY23 position and £0.5m is the net increase across other services. These are offset by a reduction in Covid Vaccination costs of £4.8m.
- 12. Drugs are £2.5m higher than last year due to higher sales in OPS post Covid-19.
- 13. Premises and Fixed Plant £2.0m less than last year due to changes in the accounting treatment of leases.
- 14. Purchase of Healthcare is £6.6m higher than last year due to Provider Collaboratives, in particular the full year effect of the Secure Provider Collaborative and a change in the lead provider payment regime.
- 15. Other Non Pay Expenditure is £1.8m higher than last year due to a £0.8m increase in the Bad Debt provision; an increase in Research & Development costs of £0.4m; and a net increase of £0.6m across other areas.

## Out of Area Treatments (OATs)

OATs are **£1,724k** overspent at month 4 (**£1,483k** overspend in Oxfordshire and **£241k** in Buckinghamshire). This includes the costs Elysium Block Contract Beds at Potter Bar and Chadwick Lodge, these have been reduce from 21 beds to 5 Beds.







## Variance to Plan by Month




Confidential

<b>PLAN</b>	<b>Month 1</b>	<b>Month 2</b>	<b>Month 3</b>	<b>Month 4</b>	<b>Month 5</b>
	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>
Clinical Income	38.3	37.5	38.9	34.2	40.5
Other Operating Income	4.9	5.2	4.8	5.7	6.5
<b>Operating Income Total</b>	<b>43.3</b>	<b>42.7</b>	<b>43.6</b>	<b>39.9</b>	<b>47.0</b>
Employee Benefits Expenses	26.2	25.9	26.3	26.9	29.0
Other Operating Costs	15.3	15.0	14.3	16.0	16.4
<b>Operating Expenses Total</b>	<b>41.5</b>	<b>40.9</b>	<b>40.6</b>	<b>43.0</b>	<b>45.5</b>
<b>EBITDA</b>	<b>1.8</b>	<b>1.8</b>	<b>3.1</b>	<b>3.1</b>	<b>1.5</b>
<b>ACTUAL</b>	<b>Month 1</b>	<b>Month 2</b>	<b>Month 3</b>	<b>Month 4</b>	<b>Month 5</b>
	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>
Clinical Income	38.6	39.8	38.0	37.6	40.9
Other Operating Income	6.8	7.9	6.6	7.2	6.3
<b>Operating Income Total</b>	<b>45.4</b>	<b>47.6</b>	<b>44.6</b>	<b>44.8</b>	<b>47.2</b>
Employee Benefits Expenses	29.5	28.0	29.5	28.4	30.7
Other Operating Costs	14.4	17.8	13.6	17.0	13.8
<b>Operating Expenses Total</b>	<b>43.9</b>	<b>45.8</b>	<b>43.1</b>	<b>45.5</b>	<b>44.6</b>
<b>EBITDA</b>	<b>1.5</b>	<b>1.9</b>	<b>1.5</b>	<b>0.7</b>	<b>2.6</b>
<b>VARIANCE</b>	<b>Month 1</b>	<b>Month 2</b>	<b>Month 3</b>	<b>Month 4</b>	<b>Month 5</b>
	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>	<b>£m</b>
Clinical Income	0.3	2.3	- 0.8	3.3	0.4
Other Operating Income	1.9	2.7	1.8	1.5	- 0.2
<b>Operating Income Total</b>	<b>2.2</b>	<b>5.0</b>	<b>1.0</b>	<b>4.9</b>	<b>0.2</b>
Employee Benefits Expenses	- 3.3	- 2.1	- 3.2	- 1.5	- 1.7
Other Operating Costs	0.9	- 2.8	0.6	- 1.0	2.6
<b>Operating Expenses Total</b>	<b>- 2.4</b>	<b>- 4.9</b>	<b>- 2.6</b>	<b>- 2.5</b>	<b>0.9</b>
<b>EBITDA</b>	<b>- 0.3</b>	<b>0.1</b>	<b>- 1.6</b>	<b>2.4</b>	<b>1.1</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16



## 2. Clinical Income

CLINICAL INCOME	YTD at month 5			
	Plan £'000	Actual £'000	Variance £'000	Variance %
Any Qualified Provider	902	902	0	0%
Berks HC NHS FT - Liaison & Diversion	83	83	(0)	0%
Buckinghamshire Block	13,951	15,425	1,474	11% ①
Buckinghamshire County Council	4,167	4,267	100	2% ②
Buckinghamshire S75 (pooled budget)	1,497	1,511	15	1%
Cost per Case Income	314	528	213	68% ③
ICB's Income	0	19	19	0%
ICB's Low Volume Activity	149	149	0	0%
ICB's Non Contract Activity	61	36	(25)	0%
Income from NHS Trusts	789	1,024	235	30% ④
NHS BOB ICB - Bucks	9,032	9,032	0	0%
NHS BOB ICB - Bucks CHC	377	377	(0)	0%
NHS BOB ICB - Bucks Cquin	102	102	0	0%
NHS BOB ICB - CAMHS	2,510	2,510	(0)	0%
NHS BOB ICB - CAMHS Cquin	22	22	0	0%
Nhs BOB ICB - Community	13,346	13,559	213	2% ⑤
Nhs BOB ICB - IAPT	2,062	2,062	0	0%
Nhs BOB ICB - IAPT Cquin	20	20	(0)	0%
Nhs BOB ICB - LD	1,217	1,217	(0)	0%
Nhs BOB ICB - LD Cquin	15	15	0	0%
Nhs BOB ICB - Luther St	127	127	0	0%
Nhs BOB ICB - Mental Health	7,093	7,093	(0)	0%
Nhs BOB ICB - MH CQUIN	28	28	0	0%
Nhs BOB ICB - OBC	10,181	9,564	0	0%
Nhs BOB ICB - OBC Cquin	4	4	(0)	0%
NHS BOB ICB - Podiatry	594	594	(0)	0%
NHS BOB ICB - Podiatry Cquin	7	7	0	0%
Nhs BOB ICB - SDF Investments	789	789	(0)	0%
NHS BSW	4,543	4,799	257	6% ⑥
Nhs BSW ICB - Block	2,762	2,762	(0)	0%
Nhs BSW ICB - Community	41	41	0	0%
Nhs BSW ICB - Community Cquin	151	151	0	0%
Nhs BSW ICB - Cquin	34	34	(0)	0%
Nhs BSW ICB - Eating Disorders	191	191	(0)	0%
Nhs England - SAI	490	488	(1)	0%
NHS England Block	51,828	51,755	(73)	0%
NHS England FCAMHS	471	471	0	0%
NHS Northamptonshire	242	242	0	0%
Nhs Northamptonshire ICB	159	159	0	0%
Nhs Northamptonshire ICB - Cquin	2	2	0	0%
Other CCGs Income	0	678	678	0% ⑦
Other Local Authority	14	21	7	46%
Oxfordshire Block - CAMHS	3,798	4,240	442	12% ⑧
Oxfordshire Block - IAPT	3,128	3,455	326	10% ⑨
Oxfordshire Block - Learning Disabilities	2,017	2,094	77	4%
Oxfordshire Block - main contract	26,750	27,351	601	2% ⑩
Oxfordshire Block - OBC	15,277	16,305	412	3% ⑪
Oxfordshire Cost & Volume	1,900	1,900	0	0%
Oxfordshire County Council	4,695	5,147	453	10% ⑫
Oxfordshire S75 (pooled budget)	752	752	0	0%
Personal Injury Compensation	47	33	(14)	-30%
Private Patients	86	99	13	16%
Wales Cost & Volume	400	389	(11)	-3%
Wiltshire Borough Council	216	216	0	0%
<b>Clinical Income Total</b>	<b>189,431</b>	<b>194,842</b>	<b>5,411</b>	<b>3%</b>

Clinical income is **£5,411k** favourable to plan at month 5. Material variances to the plan are:

- Buckinghamshire Block is **£1,474k** favourable due to the release of FY22 deferred income to offset expenditure.
- Buckinghamshire County Council is **£100k** favourable due to the release of FY22 deferred income to offset expenditure.
- Cost per case income is **£213k** favourable mainly in the Oxfordshire & BSW and Buckinghamshire directorates.
- Income from NHS Trusts is **£235k** favourable due to income received for a service user on Woodlands ward.
- NHS BOB ICB Community - **£213k** favourable to match additional expenditure in Children's Continuing Healthcare.
- NHS BSW **£257k** favourable due to release of deferred income
- Other CCG Income **£678k** favourable mainly due to the recover of costs in Children's Continuing Healthcare **£540k**.
- Oxfordshire Block CAMHS **£442k** favourable due to release of deferred income and DWP pass through income.
- Oxfordshire Block IAPT **£326k** favourable due to release of deferred income.
- Oxfordshire Block main contract **£601k** favourable due to release of deferred investment income.
- Oxfordshire Block OBC **£6412k** favourable due to release of deferred investment income.
- Oxfordshire County Council **£453k** favourable due to prior year inflation funding accounted for in FY23.



### 3. Non-Clinical Income

Confidential

NON-CLINICAL INCOME	YTD at month 5			
	Plan £'000	Actual £'000	Variance £'000	Variance %
Education & Training	6,939	8,265	1,326	19%
Other Operating Income	15,137	21,623	6,486	43%
Research & Development	4,943	4,863	(80)	-2%
<b>Non- Clinical Income Total</b>	<b>27,019</b>	<b>34,751</b>	<b>7,732</b>	<b>29%</b>

- Education & Training income **£1,326k** favourable: **£222k** Apprenticeship income received for trainees matching pay expenditure and backdated Apprenticeship levy income; Oxfordshire & BSW **£669k** favourable for various training posts where budget has not been set – largely within IAPT and CAMHS services; **£118k** Oxfordshire Training Hub; Other **£317k**.
- Other Operating Income **£6,486k** favourable: retrospective top up payments for the costs of the mass vaccination centres **£6,059k**; Oxford Pharmacy Store higher sales than planned **£259k**; Other **£168k**.
- Research & Development income is **£80k** adverse offset with clinical income received in the Academic Health Science Network.

## 4. Agency



At month 5 **£20.4m** has been spent on agency staff (excluding **£5.5m** for agency staff at the Covid mass vaccination sites). This is **15%** of total staff costs. Note that the graphs above exclude spend in the Covid-19 vaccination centres to show a normalised position.

Please refer to the HR report for further details.

## 6. Cost Improvement Plan

CIP / PIP Delivery at Month 05 FY23							
Projects	FY Target	FY Plan	YTD Target	YTD Actual	YTD Variance	Forecast	Forecast Variance
	£'000	£'000	£'000	£'000	£'000	£'000	£'000
CIP Programme	7,845	3,319	3,269	1,345	-1,924	2,986	-4,858
PIP Schemes / Agency Reduction	9,044	9,044	1,614	445	-1,169	3,131	-5,913
Covid Costs Reduction	0	0	0	0	0	0	0
<b>Total</b>	<b>16,889</b>	<b>12,364</b>	<b>4,882</b>	<b>1,790</b>	<b>-3,093</b>	<b>6,118</b>	<b>-10,772</b>

### CIP Programme:

- In line with NHS efficiency requirements that Trust has a CIP target of **£7.9m**. Budget reductions totalling **£7.9m** have been applied to all Directorates at the start of Financial year. Plans to deliver the **£7.9m** target total **£3.3m**. Savings reported as at the end of month 5 are **£1.3m**, **£1.9m** adverse to target.

### PIP Programme Schemes :

- The PIP programme encompasses schemes that are cost avoidance i.e. expenditure items for which there is no funding. It is centred on initiatives to reduce agency costs e.g. price reductions and usage. The target is a **£9.0m** reduction. The IQRA programme has delivered **£0.4m** reductions as at the end of month 5, **£1.2m** adverse to target.

### Covid Cost Reduction:

- Covid cost reductions is a cost avoidance programme to address the continuance of expenditure incurred during the 2 year covid period. It is centred on initiatives to reduce staffing costs and the use of ISP contracted beds that have become business as usual and to challenge there validity in the context of the retained covid budget **£7.3m**.

## 7. Statement of Financial Position

## Statement of Financial Position as at 31st August 2022

31 March 2022		Month 4 FY22	Month 5 FY23	Movement	
£'000		£'000	£'000	Year to date £'000	In month £'000
<b>Non-current assets</b>					
6,390	Intangible Assets	5,754	5,642	(749)	(112)
155,907	Property, plant and equipment	156,056	156,389	482	333
0	Finance Leases	27,060	26,602	26,602	(458)
487	Trade and other receivables	499	499	12	0
<b>162,784</b>	<b>Total non-current assets</b>	<b>189,370</b>	<b>189,133</b>	<b>26,348</b>	<b>(238)</b>
<b>Current Assets</b>					
2,003	Inventories	2,465	2,217	214	(248)
19,702	Trade and other receivables	38,766	31,831	12,129	(6,935)
	Non-current assets held for sale	0	0	0	0
89,517	Cash and cash equivalents	65,260	83,120	(6,397)	17,859
<b>111,223</b>	<b>Total current assets</b>	<b>106,491</b>	<b>117,168</b>	<b>5,945</b>	<b>10,676</b>
<b>Current Liabilities</b>					
(75,128)	Trade and other payables	(68,622)	(78,850)	(3,722)	(10,228)
(2,817)	Borrowings	(2,183)	(2,237)	580	(55)
	Other financial liabilities	(1,788)	(1,788)	(1,788)	0
0	Finance Leases	(5,481)	(5,481)	(5,481)	0
(2,473)	Provisions	(2,757)	(2,985)	(512)	(228)
(22,784)	Deferred income	(22,436)	(21,730)	1,054	705
<b>(103,203)</b>	<b>Total Current Liabilities</b>	<b>(103,267)</b>	<b>(113,071)</b>	<b>(9,869)</b>	<b>(9,805)</b>
<b>Non-current Liabilities</b>					
	Trade and other payables	0	0	0	0
(15,784)	Borrowings	(16,433)	(16,383)	(599)	50
0	Finance Leases	(22,148)	(21,693)	(21,693)	454
(4,524)	Provisions	(4,361)	(4,169)	356	193
(1,132)	Other Liabilities	(1,132)	(1,132)	0	0
<b>(21,440)</b>	<b>Total non-current liabilities</b>	<b>(44,074)</b>	<b>(43,377)</b>	<b>(21,937)</b>	<b>697</b>
<b>149,364</b>	<b>Total assets employed</b>	<b>148,521</b>	<b>149,852</b>	<b>488</b>	<b>1,331</b>
<b>Financed by (taxpayers' equity)</b>					
107,619	Public Dividend Capital	107,619	107,619	1	0
27,469	Revaluation reserve	27,471	27,446	(23)	(25)
	Other reserves	0	0	0	0
14,276	Income & expenditure reserve	13,431	14,787	511	1,356
<b>149,364</b>	<b>Total taxpayers' equity</b>	<b>148,521</b>	<b>149,852</b>	<b>489</b>	<b>1,331</b>

- Non-current assets have increased by **£26.3m** in-year. The in-year increase is driven by the capitalisation of **£28.9m** of leased assets in accordance with the accounting standard IFRS16 which was adopted by the Trust from the 1st April, and capital additions of **£2.3m** in the first 5 months of the year. These additions were offset by depreciation of **£4.8m**.
- Trade and other receivables have increased by £12.1m in year and decreased by £6.9m in month. Most of the in-year increase is due to an increase in accrued income of £7.3m (£4.5m Provider Collaborative pass through costs and £2.4m pay award income), Prepayments of £3.4m and a £1.3m increase in other receivables. Most of the decrease in month was due to the receipt of the vaccination centre income from FY22 Q4 and FY23 Q.
- Cash has decreased by **£6.3m** in year and increased by **£17.8m** in month. The decrease is in line with the cash flow statement and the increase in month is due largely to a decrease in receivables (cash-in), notably for the receipt of the Q4 and Q1 vaccinations centres income, and an increase in payables (cash-in) of £10.2m due mainly to the system outage in August which delayed payments to suppliers.
- Trade and other payables have decreased by **£3.7m** in year and **£10.2m** in month in line with net decreases in accrued expenditure and other payable balances (see note 3 above).
- Short term finance lease liabilities have increased by **£5.5m** in year due to the capitalisation of leased assets – see note 1.
- Deferred income has decreased by **£1.1m** in year and **£0.7m** in month.
- Long term finance leases have increased by **£21.6m** in year and decreased by **£0.4m** in month (repayments against liability) following the capitalisation of leased assets – see note 1.
- The in-year movements in the I&E reserve reflect the Trust's reported surplus for the year.


## 8. Cash Flow

### STATEMENT OF YEAR TO DATE CASH FLOWS

	Month 5 FY23		
	Actual £'000	Plan £'000	Variance £'000
<b>Cash flows from operating activities</b>			
Operating surplus/(deficit) from continuing operations	2,038	284	1,754
Operating surplus/(deficit) from discontinuing operations	0	0	0
<b>Operating surplus/(deficit)</b>	<b>2,038</b>	<b>284</b>	<b>1,754</b>
<b>Non-cash income and expense:</b>			
Depreciation and amortisation	4,837	4,746	91
Impairments and profit on disposal of assets	0	0	0
Income recognised in respect of capital donations (cash and non-cash)	0	0	0
(Increase)/Decrease in Trade and Other Receivables	(12,407)	5,284	(17,691)
(Increase)/Decrease in Inventories	(214)	0	(214)
Increase/(Decrease) in Trade and Other Payables	7,418	(14,531)	21,949
Increase/(Decrease) in Deferred Income	734	(2,500)	3,234
Increase/(Decrease) in Provisions	156	156	(0)
Other Movements in Operating Cashflows	0	0	0
<b>NET CASH GENERATED FROM/(USED IN) OPERATIONS</b>	<b>2,563</b>	<b>(6,561)</b>	<b>9,123</b>
<b>Cash flows from investing activities</b>			
Interest received	331	112	219
Purchase of Non Current Assets	(7,079)	(6,989)	(90)
Sale of PPE	0	0	0
<b>Net cash generated from/(used in) investing activities</b>	<b>(6,749)</b>	<b>(6,877)</b>	<b>128</b>
<b>Cash flows from financing activities</b>			
Public dividend Capital Received	0	0	0
Loans received	0	0	0
Loans repaid	0	0	0
Capital element of lease rental payments	(1,708)	(2,225)	517
Capital element of Private Finance Initiative Obligations	(150)	(150)	(0)
Interest paid	0	0	0
Interest element on leases	(112)	(107)	(5)
Interest element of Private Finance Initiative obligations	(241)	(241)	0
PDC Dividend paid	0	0	0
<b>Net cash generated from/(used in) financing activities</b>	<b>(2,211)</b>	<b>(2,723)</b>	<b>512</b>
<b>Increase/(decrease) in cash and cash equivalents</b>	<b>(6,397)</b>	<b>(16,161)</b>	<b>9,763</b>
<b>Cash and Cash equivalents at 1st April</b>	<b>89,517</b>	<b>89,517</b>	<b>0</b>
<b>Cash and Cash equivalents at 31st August</b>	<b>83,120</b>	<b>73,356</b>	<b>9,763</b>

### Summary Notes

- The cash flow movements are consistent with the comments made on the Statement of Financial Position.
- The closing cash position at Month 05 was **£83.1m**.





## 9. Working Capital Indicators

Working Capital Ratios			
Ratio	Target	Actual	Risk Status
Debtor Days	30	42	●
Debtors % > 90 days	5.0%	18.2%	●
Creditor Days	30	52	●
BPPC NHS - Value of Inv's pd within target (ytd)	95.0%	90.9%	●
BPPC Non-NHS - Value of Inv's pd within target (ytd)	95.0%	91.0%	●
Cash (£m)	74.7	83.1	●

### Summary Notes

- Debtor days at month 5 were below target.
- Debtors % over 90 days are below target due to overdue invoices, specifically with Oxfordshire CCG £1,247k and NHSE £485k.
- The Creditor days position is below plan due to the high level of accruals for Non-NHS suppliers and the below target BPPC figure.
- NHS BPPC (which represents 20% of non-pay expenditure) is on target for the year and in month at 94.9%
- Non-NHS BPPC (which represents 80% of non-pay expenditure) is below for the year and marginally below target in-month a 92.5%.
- Cash is above target, as outlined in section 7 and 8.

## 10. Capital Investment Programme

FY23-CAPITAL EXPENDITURE REPORT-AUGUST( M5)					
	Year To Date £000				
Planned Schemes	FY23 Original Plan (A)	Updated Plan (B)	YTD Plan (C)	YTD Actual Expenditure (D)	Variance (B-D)
Operational Estates	1,117	1,117	389	149	240
Estates PDC Projects	-	780	98	-	98
Transformatonal Estates	1,081	1,381	275	82	193
Highfield PICU	5,664	5,664	1,898	1,572	326
IM&T Clinical Systems	1,775	1,771	528	(170)	698
IT Capital	-	1,149	327	512	(185)
PFI	-	-	1	7	(5)
Medical Equipment	300	300	125	-	125
Global Digital Exemplar DoH Funding FY19	300	-	-	(17)	17
<b>Sub Total</b>	<b>9,937</b>	<b>12,162</b>	<b>3,640</b>	<b>2,136</b>	<b>1,505</b>
<b>High Risk Projects</b>	<b>300</b>	<b>2,981</b>	<b>373</b>	<b>155</b>	<b>217</b>
<b>Grand Total</b>	<b>9,937</b>	<b>15,143</b>	<b>4,013</b>	<b>2,291</b>	<b>1,722</b>

- The Trust received an ICS capital allocation of **£9,937k**. In addition, the Trust is also able to draw on funding from the sale of Trust properties (Shrublands and Harlow - £1,382k), VAT credit reclaims £1,000k and £422k NHS Digital Unified Tech Funding (UTF) in relation to devices and infrastructure and other estate backed PDC £780. In total therefore, the Trust has **£15,143k** capital funding available in FY23.
- The first phase of the FY23 capital plan totals **£12,162k** from a total funding pot of **£15,143k**. The balance of funding will be spent on a range of high-risk projects totalling **£2,981k**. The resulting funding shortfall of **£1,623k** will be managed as part of the ICS's overall capital allocation.
- The year to date actual spend is **£2,291k**.

## 11. Reconciliation to NHSE/I Template

The financial figures reported in this report are taken directly from the finance ledger. The financial figures reported to NHSE/I each month differ from these figures as they exclude income and costs related to the Section 75 pooled budget and are some minor adjustments to the categories certain items are reported under. The table below provides a reconciliation between the figures reported in this board report to the figures reported on the NHSI template.

YTD Actuals at month 5 FY22						
	Board Report	Remove Section 75 Income and Costs	Category Changes	National supplied PPE	NHSI Template	
	£m	£m		£m	£m	£m
Clinical Income	194.8	-1.8				193.0
Other Operating Income	34.8					34.8
<b>Operating Income, Total</b>	<b>229.6</b>	<b>-1.8</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>227.8</b>
Employee Benefit Expenses (Pay)	146.1	-1.7				144.4
Other Operating Expenses	76.7	-0.1				76.5
<b>Operating Expenses, Total</b>	<b>222.8</b>	<b>-1.8</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>221.0</b>
Non-Operational Income						0.0
<b>EBITDA</b>	<b>6.8</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>6.8</b>
Profit/(Loss) on asset disposal	-0.1					-0.1
Depreciation and Amortisation	4.8					4.8
Asset Impairment	0.0					0.0
Interest	0.1					0.1
Other Finance Charge	0.3					0.3
PDC Dividend	1.1					1.1
<b>Surplus/ (Deficit)</b>	<b>0.5</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.5</b>